CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows (used in) from Operating Activities:
Net loss	$ (823,027)	$ (126,660)
Adjustments to reconcile net loss to net cash (used in) from operating activities:
Depreciation and amortization expense	81,213	64,215
Change in fair value of contingent consideration	(2,800)	(9,525)
Change in fair value of warrant liabilities	(5,696)	8,383
Goodwill impairment loss	354,000	0
Intangible assets disposals	1,467	0
Loss on extinguishment of debt	0	1,428
Fixed asset abandonment	2,200	0
Amortization of debt issuance costs	3,872	2,743
Non-cash lease expense	2,010	8,367
Class A common shares issued for bonus award	0	2,194
Stock-based compensation, net	7,285	42,641
Paid in kind interest expense	13,564	0
Credit loss on other assets	62,000	0
Gain on Sale Transaction	(386)	0
Changes in operating assets and liabilities:
Accounts receivable, net	146,317	(75,913)
Other assets	1,216	10,885
Prepaid expenses and other current assets	1,979	(47,492)
Interest accrued due to sellers	0	100
Accounts payable and accrued expenses (Related parties comprised $(2,875) and $3,047 for the nine months ended September 30, 2023 and 2022, respectively)	46,309	30,955
Other liabilities	23,811	3,521
Net cash (used in) provided by operating activities	(84,666)	(84,158)
Cash Flows from (used in) Investing Activities:
Purchase of property and equipment (Related parties comprised $983 and $0 for the nine months ended September 30, 2023 and 2022, respectively)	(18,139)	(39,061)
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired	0	(4,995)
Payments to sellers	(6,557)	(4,097)
Proceeds from Sale Transaction	33,542	0
Net cash provided (used in) by investing activities	8,846	(48,153)
Cash Flows from (used in) Financing Activities:
Payments of long-term debt	(4,834)	(4,833)
Debt issuance costs	(9,256)	(88)
Proceeds from long-term debt	150,000	0
Proceeds from CS Revolving Line of Credit	165,000	25,000
Repayments of CS Revolving Line of Credit	(209,000)	(25,000)
Proceeds from insurance financing arrangements	2,690	2,529
Payments of principal on insurance financing arrangements	(2,201)	(2,070)
Other	(2,577)	(2,300)
Net cash provided (used in) by financing activities	89,822	(6,762)
Net increase (decrease) in cash, cash equivalents and restricted cash	14,002	(139,073)
Cash, cash equivalents and restricted cash at beginning of year	27,329	163,170
Cash, cash equivalents and restricted cash at end of period	41,331	24,097
Supplemental cash flow information:
Interest paid	57,603	38,233
Income taxes paid	148	82
Non-cash investing and financing activities:
Additional principal additions from long term	7,866	0
Debt discount addition	(7,866)	0
Right-of-use assets obtained in exchange of lease liabilities	16,922	58,595
Issuance of Class A common stock for acquisitions	14,527	54,914
Contingent consideration liability in connection with acquisitions	0	1,500
Contingent consideration assets in connection with acquisitions	0	(5,600)
Due to sellers in connection with acquisitions	0	1,530
Changes to construction in process reflected through accounts payable	(1,993)	5,665
Humana Affiliate Provider clinic leasehold improvements	(294)	5,878
Employee Stock Purchase Plan issuance	1,924	11,377
Warrants issued	$ 45,698	$ 0